Zentalis Pharmaceuticals, Inc.
ZNTL
$1.43
-$0.08-5.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -213.34M | -179.28M | -194.65M | -218.90M | -292.19M |
| Total Depreciation and Amortization | 1.29M | 1.31M | 1.34M | 1.35M | 1.39M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.79M | 5.41M | 14.10M | 13.46M | 77.12M |
| Change in Net Operating Assets | -16.54M | 804.00K | 12.84M | -6.42M | 5.86M |
| Cash from Operations | -170.86M | -171.76M | -166.38M | -210.51M | -207.82M |
| Capital Expenditure | -221.00K | -394.00K | -485.00K | -623.00K | -583.00K |
| Sale of Property, Plant, and Equipment | 65.00K | 65.00K | 65.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 176.72M | 102.55M | -63.06M | -24.41M | -43.88M |
| Cash from Investing | 176.56M | 102.22M | -63.48M | -25.03M | -44.46M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 349.00K | 349.00K | 566.00K | 237.18M | 237.30M |
| Repurchase of Common Stock | -241.00K | -241.00K | -241.00K | -241.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 108.00K | 108.00K | 325.00K | 236.94M | 237.30M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.81M | -69.43M | -229.53M | 1.39M | -14.98M |